Cabotegravir is an HIV-1 Integrase Strand Transfer Inhibitor (INSTI). As a novel antiretroviral drug, it is used in combination with rilpivirine to provide an innovative treatment regimen for patients infected with HIV-1.
How Effective is Cabotegravir in Treatment?
Viral Suppression Efficacy
Cabotegravir binds to the active site of HIV integrase, blocking the process of viral DNA integration and effectively inhibiting HIV-1 replication.
Clinical studies have shown that this drug exhibits favorable antiviral activity against multiple HIV-1 subtypes.
When used in combination with rilpivirine, it can provide sustained therapeutic effects for patients who have already achieved virological suppression.
Combined Medication Regimen
Cabotegravir must be used in combination with rilpivirine to form a complete antiretroviral treatment regimen.
This combination is not suitable for co-administration with other anti-HIV drugs.
When used as an oral lead-in therapy, patients need to take it continuously for approximately one month to assess their tolerance to cabotegravir, preparing for the subsequent use of the long-acting injectable formulation.
Who is Cabotegravir Suitable for?
Characteristics of Target Patients
Cabotegravir is indicated for adult patients infected with HIV-1 who have achieved virological suppression.
These patients should be receiving stable antiretroviral therapy and have no history of treatment failure.
They should have no known or suspected resistance to cabotegravir or rilpivirine.
Medication Monitoring for Cabotegravir
Pre-Treatment Assessment
Allergy history, particularly reactions to other integrase inhibitors.
Baseline liver conditions and results of liver function tests.
Mental health status and history of depressive symptoms.
Concomitant medication use to avoid potential drug-drug interactions.
Key Monitoring During Treatment
Hypersensitivity Reaction Monitoring: If symptoms such as rash accompanied by fever, malaise, fatigue, musculoskeletal pain, blisters, oral lesions, conjunctivitis, facial edema, or hepatitis occur, discontinue the drug immediately and seek medical attention.
Liver Function Monitoring: Regularly check liver enzyme levels. Promptly manage hepatotoxicity symptoms such as jaundice, dark urine, pale stools, nausea, vomiting, loss of appetite, or pain in the right upper abdomen.
Mental Status Monitoring: Pay attention to mood changes and depressive symptoms; conduct professional evaluations if necessary.
Drug-Drug Interaction Monitoring: Special attention should be paid to interactions with antacids, anticonvulsants, and antimycobacterial drugs.
Medication Adherence Management
Cabotegravir should be taken at a fixed time every day. When administered together with rilpivirine, it should be taken with food.
If a dose is missed, take it as soon as possible to avoid treatment interruption, which may lead to viral rebound and the development of drug resistance.
When used as an alternative to the injectable formulation, patients must complete the oral treatment course strictly as scheduled to ensure treatment continuity.
